The Journal of Clinical Psychiatry

Publication Venue For
- A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. 74. 2013
- Shift work disorder case studies: applying management principles in clinical practice.. 73:e25. 2012
- How the circadian rhythm affects sleep, wakefulness, and overall health: background for understanding shift work disorder.. 73:e05. 2012
- Dr Barber and colleagues reply. 73:718-720. 2012
- A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression (Journal of Clinical Psychiatry (2010) 71, 1 (32-40)). 72:1157. 2011
- Handbook of Clinical Child Neuropsychology, 3rd ed. 72:726-726. 2011
- Recognition and Prevention of Major Mental and Substance Use Disorders. 70:1060-1060. 2009
- Dr. Nejtek and colleagues reply. 70:936-937. 2009
- Suicidal events in the Treatment for Adolescents With Depression Study (TADS).. 70:741-747. 2009
- Dr. McClintock and Colleagues reply. 69:1662-1663. 2008
- A history of the concept of atypical depression. 68:10-15. 2007
- Implementation of the Texas Medication Algorithm Project patient and family education program.. 67:1362-1372. 2006
- Lifetime trauma exposure in veterans with military-related posttraumatic stress disorder: association with current symptomatology.. 67:1346-1353. 2006
- Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.. 67:1354-1361. 2006
- Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression.. 67:688-695. 2006
- Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.. 67:453-460. 2006
- Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report.. 67:185-195. 2006
- Botulinum toxin treatment of social anxiety disorder with hyperhidrosis: a placebo-controlled double-blind trial.. 67:30-36. 2006
- Bupropion extended release compared with escitalopram: Effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. 67:736-746. 2006
- Children of currently depressed mothers: a STAR*D ancillary study.. 67:126-136. 2006
- Foreword. After the tsunami: mental health challenges to the community for today and tomorrow.. 67 Suppl 2:3-8. 2006
- High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.. 67:15-22. 2006
- Managing patients with vascular disease and depression. 67:1633-1644. 2006
- Pharmacologic treatment of acute and chronic stress following trauma: 2006.. 67 Suppl 2:34-39. 2006
- Practical assessment and evaluation of mental health problems following a mass disaster.. 67 Suppl 2:26-33. 2006
- Risks versus benefits of different types of long-acting injectable antipsychotics.. 67 Suppl 5:15-18. 2006
- The extent and impact of mental health problems after disaster.. 67 Suppl 2:9-14. 2006
- Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder.. 66:1441-1446. 2005
- Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.. 66:1161-1168. 2005
- Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes.. 66:1097-1104. 2005
- A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder.. 66:997-1001. 2005
- Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D.. 66:1002-1011. 2005
- Possible bipolar nature of irritability in major depressive disorder.. 66:1072. 2005
- Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy.. 66:1016-1020. 2005
- Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment?. 66:455-468. 2005
- Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial.. 66:323-330. 2005
- Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction.. 66:346-352. 2005
- Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study.. 66:159-166. 2005
- The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients.. 66:49-51. 2005
- Definitions, measurements, and management in insomnia. 65:5-7. 2004
- Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone.. 65:1666-1673. 2004
- Update on posttraumatic stress disorder. 65:3. 2004
- Body mass index and future schizophrenia in Israeli male adolescents.. 65:1546-1549. 2004
- Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia.. 65:1128-1137. 2004
- A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus.. 65:857-863. 2004
- Suicidality as a possible side effect of antidepressant treatment.. 65:742-749. 2004
- A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes.. 65:478-484. 2004
- Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.. 65:551-556. 2004
- Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report.. 65:485-491. 2004
- The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.. 65:500-508. 2004
- Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness.. 65:361-372. 2004
- The cost consequences of treatment-resistant depression.. 65:341-347. 2004
- Changing how we think about insomnia. 65:44-46. 2004
- Classifying insomnia in a clinically useful way.. 65 Suppl 8:36-43. 2004
- Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety.. 65 Suppl 1:55-62. 2004
- Introduction: Definitions, measurements, and management in insomnia.. 65 Suppl 8:5-7. 2004
- Long-term treatment and prevention of posttraumatic stress disorder.. 65 Suppl 1:44-48. 2004
- Panel discussion: changing how we think about insomnia.. 65 Suppl 8:44-46. 2004
- Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.. 65:57-61. 2004
- The changing perspective on chronic insomnia management.. 65 Suppl 8:20-25. 2004
- Use of benzodiazepines in social anxiety disorder, generalized anxiety disorder, and posttraumatic stress disorder.. 65 Suppl 5:29-33. 2004
- Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method.. 64:680-690. 2003
- Bipolar disorder: Origin, recognition, and treatment. 64:3. 2003
- Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient.. 64 Suppl 11:14-18. 2003
- Conclusions. Bipolar disorder: Origin, recognition, and treatment. 64:28. 2003
- Response, remission, and recovery in bipolar disorders: what are the realistic treatment goals?. 64 Suppl 6:18-22. 2003
- The impact of treatment-resistant depression on health care utilization and costs.. 63:963-971. 2002
- Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.. 63:931-935. 2002
- Selecting methodologies for the evaluation of differences in time to response between antidepressants.. 63:694-699. 2002
- Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination.. 63:709-716. 2002
- Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression.. 63:493-500. 2002
- Antidepressant selection: Focus on nefazodone. 63:7-9. 2002
- Clinical use of nefazodone in major depression: a 6-year perspective.. 63 Suppl 1:18-31. 2002
- Effects of antidepressants on sleep: Focus on nefazodone. 63:27-31. 2002
- Introduction - Pathophysiology of depression: The emerging role of substance P. 63:4-5. 2002
- Overview of psychiatric disorders and the role of newer antidepressants.. 63 Suppl 1:3-9. 2002
- Pathophysiology of depression: The emerging role of substance P. 63:4-5. 2002
- Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose.. 62:993-994. 2001
- Texas Medication Algorithm Project: development and feasibility testing of a treatment algorithm for patients with bipolar disorder.. 62:439-447. 2001
- Which depressed patients respond to nefazodone and when?. 62:158-163. 2001
- Advances and emerging treatments in social phobia. 62:4. 2001
- Consensus statement on depression, anxiety, and cardiovascular disease.. 62 Suppl 8:24-27. 2001
- Consensus statement on depression, anxiety, and functional gastrointestinal disorders.. 62 Suppl 8:48-51. 2001
- Consensus statement on depression, anxiety, and oncology.. 62 Suppl 8:64-67. 2001
- Consensus statement on transcultural issues in depression and anxiety from the International Consensus Group on Depression and Anxiety.. 62 Suppl 13:47-55. 2001
- Contemporary management of comorbid anxiety and depression in geriatric patients.. 62 Suppl 12:30-35. 2001
- Introduction - Chronic major depression: A review and update. 62:3-4. 2001
- Introduction: Recognizing treatment-resistant depression. 62:3-4. 2001
- Pharmacotherapy of generalized anxiety disorder.. 62 Suppl 11:46-50. 2001
- What is generalized anxiety disorder?. 62 Suppl 11:4-12. 2001
- EMDR for treatment of PTSD.. 61:784. 2000
- Further discussion of EMDR for treatment of PTSD.. 61:785-786. 2000
- Omission of bupropion as a recommended treatment for PTSD.. 61:786. 2000
- Psychodynamic psychotherapy for PTSD.. 61:787. 2000
- A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients.. 61:559-568. 2000
- The Texas Medication Algorithm Project Patient and Family Education Program: a consumer-guided initiative.. 61:477-486. 2000
- Low-dose amphetamine salts and adult attention-deficit/hyperactivity disorder.. 61:414-417. 2000
- New strategies for the treatment of posttraumatic stress disorder. 61:3-4. 2000
- Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome.. 61 Suppl 5:52-56. 2000
- Posttraumatic stress disorder: epidemiology and health-related considerations.. 61 Suppl 7:5-13. 2000
- The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms.. 60:649-657. 1999
- Zolpidem for persistent insomnia in SSRI-treated depressed patients.. 60:668-676. 1999
- Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.. 60:528-535. 1999
- The economic burden of anxiety disorders in the 1990s.. 60:427-435. 1999
- Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project.. 60:284-291. 1999
- The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder.. 60:142-156. 1999
- Brain imaging correlates.. 60 Suppl 15:50-54. 1999
- Consensus statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety.. 60 Suppl 7:54-61. 1999
- Management of posttraumatic stress disorder: diagnostic and therapeutic issues.. 60 Suppl 18:33-38. 1999
- Mental health care from the public perspective: the Texas Medication Algorithm Project.. 60 Suppl 3:16-20. 1999
- Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients.. 60:815-818. 1999
- The underrecognition and undertreatment of depression: what is the breadth and depth of the problem?. 60 Suppl 7:4-9. 1999
- Treatment of posttraumatic stress disorder. 60:6-74. 1999
- The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies.. 59:589-597. 1998
- The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine.. 59:598-607. 1998
- Open trial of nefazodone for combat-related posttraumatic stress disorder.. 59:460-464. 1998
- Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms.. 59:345-351. 1998
- Brain mechanisms of social anxiety disorder: Comments. 59:10-11. 1998
- Bupropion sustained release: a therapeutic overview.. 59 Suppl 4:25-31. 1998
- Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety.. 59 Suppl 8:47-54. 1998
- Early recognition of Alzheimer's disease: what is consensual? What is controversial? What is practical?. 59 Suppl 13:6-18. 1998
- How is recovery from social anxiety disorder defined?: Comments. 59:17-19. 1998
- Introduction: Beyond SSRIs. 59:3-4. 1998
- Pharmacotherapy of social anxiety disorder.. 59 Suppl 17:47-53. 1998
- Psychotherapy in the overall management strategy for social anxiety disorder: Comments. 59:45-46. 1998
- Social anxiey disorder: Etiology and early clinical presentation: Comments. 59:32. 1998
- The long-term treatment of panic disorder.. 59 Suppl 8:17-21. 1998
- The nature of social anxiety disorder: Comments. 59:25-26. 1998
- The undertreatment of dysthymia.. 58:59-65. 1997
- Biological therapies for posttraumatic stress disorder: an overview.. 58 Suppl 9:29-32. 1997
- Repairing the shattered self: recovering from trauma.. 58 Suppl 9:3-4. 1997
- Use of benzodiazepines in panic disorder.. 58 Suppl 2:26-28. 1997
- Functional status in depressed patients: the relationship to disease severity and disease resolution.. 57:588-592. 1996
- The dexamethasone suppression test in patients with mood disorders.. 57:470-484. 1996
- The suppression of nightmares with guanfacine.. 57:371. 1996
- Medication optimization during clozapine treatment.. 57:307-308. 1996
- Use of ECT in treatment of depression in patients with diabetes mellitus.. 57:138. 1996
- Carbon monoxide-related organic mood disorder successfully treated with ECT.. 56:332-333. 1995
- A combined treatment approach to anxiety in the medically ill.. 56 Suppl 2:14-19. 1995
- Social phobia: outlook for the '90s.. 55:503-510. 1994
- Bupropion in chronic low back pain.. 55:362. 1994
- Treatment of social phobia with benzodiazepines.. 55 Suppl:28-32. 1994
- Efficacy of risperidone on positive features of schizophrenia.. 55 Suppl:18-21. 1994
- Introduction. Social phobia in review: 1993. 54:3-4. 1993
- Magnetic resonance spectroscopy in social phobia: preliminary findings.. 54 Suppl:19-25. 1993
- Dexamethasone suppression test and onset of poststroke depression in patients with ischemic infarction.. 54:343-348. 1993
- Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia.. 54:88-95. 1993
- Issues in the treatment of major depression: Selection, efficacy, and safety. 53:3-4. 1992
- Simultaneous major depression and panic disorder: treatment with electroconvulsive therapy.. 53:12-15. 1992
- A 102-center prospective study of seizure in association with bupropion.. 52:450-456. 1991
- Levels of urinary free cortisol in social phobia.. 52 Suppl:41-42. 1991
- The Brief Social Phobia Scale.. 52 Suppl:48-51. 1991
- Continuation treatment of panic disorder with high-potency benzodiazepines.. 51 Suppl A:31-37. 1990
- Shared features of neuroleptic malignant syndrome and alcohol abuse complications.. 51:523. 1990
- Bupropion dosing recommendations.. 51:83. 1990
- Edgar Allan Poe's ''William Wilson'' and Capgras syndrome (Reply). 51:389. 1990
- Seizures and bupropion: a review.. 50:256-261. 1989
- Hospitalized schizophrenic patient views about seclusion.. 50:174-177. 1989
- Fluoxetine versus trazodone in the treatment of outpatients with major depression.. 49:422-426. 1988
- A comparison of self-reported versus clinician-related symptoms in depression.. 48:246-248. 1987
- An outpatient evaluation of phenelzine and imipramine.. 48:143-146. 1987
- Secondary agoraphobia: two case reports.. 45:482-483. 1984
- A comparison of the cortisol suppression index and the dexamethasone suppression test.. 45:431-432. 1984
- Funeral mania in recurrent bipolar affective disorders: reports of three cases.. 45:310-311. 1984
- Patient compliance with MAO inhibitor therapy.. 45:78-80. 1984
- Practical aspects of MAO inhibitor therapy.. 45:81-84. 1984
- The importance of dose in isocarboxazid therapy.. 45:49-52. 1984
- MAO inhibitor therapy in trichotillomania associated with depression: case report.. 45:267-268. 1984
- Classification of depressive disorders: A multiaxial approach. 45:5-13. 1984
- Funeral mania in recurrent bipolar affective disorders: Reports of three cases. 45:310-311. 1984
- Relationships among the TRH, REM latency, and dexamethasone suppression tests: preliminary findings.. 44:23-29. 1983
- A double-blind comparison of bupropion and amitriptyline in depressed inpatients.. 44:115-117. 1983
- Electroconvulsive therapy does not change serum CK, LD, or LD isoenzymes.. 43:169-170. 1982
- Viloxazine HCl in the treatment of endogenous depression: A standard (imipramine) controlled clinical study. 43:111-112. 1982
- A comparison of phenelzine and imipramine in depressed inpatients.. 42:395-397. 1981
- Neuropsychiatric manifestations of porphyria.. 41:208-213. 1980
- Lid retraction test.. 40:153. 1979
- Peroneal palsy in depression.. 39:287-292. 1978
- Pharmacotherapy of social anxiety disorder: what does the evidence tell us? 2006
- Texas Medication Algorithm Project, phase 3 (TMAP-3): clinical results for patients with a history of mania. 2003
- Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. 2003
- Toward an understanding of bipolar disorder and its origin. 2003
- Smaller orbital frontal cortex volumes associated with functional disability in depressed elders 2002
- Clinical experience with substance P receptor (NK1) antagonists in depression. 2002
- Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? 2001
- Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. 2001
- Generalized anxiety disorder: nature and course. 2001
- Neurobiological mechanisms in generalized anxiety disorder. 2001
- Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. 2000
- Best clinical practice: guidelines for managing major depression in primary medical care. 1999
- Strategies and tactics in the management of maintenance treatment for depressed patients. 1999
- The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. 1998
- Treatment algorithm use to optimize management of symptomatic patients with a history of mania. 1998
- Consensus guidelines in the treatment of major depressive disorder. 1998
- Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. 1998
- Focus on social anxiety disorder: Introduction 1998
- Panic disorder: making clinical sense of the latest research. 1997
- Strategies and tactics in the treatment of chronic depression. 1997
- Trauma: prevalence, impairment, service use, and cost. 1997
- When at first you don't succeed: sequential strategies for antidepressant nonresponders. 1997
- International advances in the treatment of social phobia. 1994
- The role of nuclear magnetic resonance imaging in psychiatric research. 1993
- Long-term treatment of social phobia with clonazepam. 1991
- Social phobia in review 1991
- Problems associated with the diagnosis of depression. 1990

Publication Venue For